|
Parameter
| |
|---|
|
Gender
| |
|
Male
|
65 (77.3 %)
|
|
Female
|
19 (22.6 %)
|
|
Age (y)
| |
|
Median (Range)
|
61 (33–75)
|
|
Performance status
| |
|
0/1/2
|
41/38/0
|
|
3/4/unknown
|
1/0/4
|
|
Histology
| |
|
Small cell carcinoma
|
19 (22.6 %)
|
|
Adenocarcinoma
|
37 (44 %)
|
|
Large-cell carcinoma
|
2 (2.4 %)
|
|
Squamous cell carcinoma
|
13 (15.5 %)
|
|
Malignant pleural mesothelioma
|
6 (7.1 %)
|
|
Thymic malignancy
|
2 (2.4 %)
|
|
Others
|
5 (6 %)
|
|
Cisplatin
| |
|
Median dose (mg/m2/day) (range)
|
80 (40–80)
|
|
Median cycle (range)
|
4 (1–6)
|
|
Anticancer drugs
| |
|
Vinorelbine
|
26 (31 %)
|
|
Etoposide
|
14 (16.7 %)
|
|
Docetaxel
|
12 (14.3 %)
|
|
Pemetrexed
|
11 (13.1 %)
|
|
Gemcitabine
|
4 (4.8 %)
|
|
S-1
|
4 (4.8 %)
|
|
Irinotecan
|
2 (2.4 %)
|
|
Others
|
11 (13.1 %)
|
|
Serum creatinine (mg/dl)
| |
|
Median (range)
|
0.72 (0.50–0.99)
|
|
eGFR (mL/min/1.73 m2)
| |
|
Median (range)
|
81.1 (59.2–113.0)
|
|
Charlson Comorbidity Index
| |
|
Median (range)
|
6 (2–10)
|
